Pfizer Inc. (PFE)
27.80
-0.32
(-1.14%)
USD |
NYSE |
Oct 02, 16:00
27.80
0.00 (0.00%)
Pre-Market: 20:00
Pfizer Enterprise Value : 210.23B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 210.23B |
| October 01, 2026 | 212.05B |
| September 30, 2026 | 214.33B |
| September 29, 2026 | 215.47B |
| September 28, 2026 | 215.47B |
| September 25, 2026 | 215.19B |
| September 24, 2026 | 213.71B |
| September 23, 2026 | 212.39B |
| September 22, 2026 | 210.97B |
| September 21, 2026 | 209.89B |
| September 18, 2026 | 209.43B |
| September 17, 2026 | 209.32B |
| September 16, 2026 | 208.29B |
| September 15, 2026 | 208.80B |
| September 14, 2026 | 209.77B |
| September 11, 2026 | 209.77B |
| September 10, 2026 | 209.37B |
| September 09, 2026 | 210.12B |
| September 08, 2026 | 210.17B |
| September 04, 2026 | 213.93B |
| September 03, 2026 | 215.99B |
| September 02, 2026 | 217.18B |
| September 01, 2026 | 214.50B |
| August 31, 2026 | 213.99B |
| August 28, 2026 | 211.14B |
| Date | Value |
|---|---|
| August 27, 2026 | 211.48B |
| August 26, 2026 | 213.08B |
| August 25, 2026 | 214.62B |
| August 24, 2026 | 211.20B |
| August 21, 2026 | 211.77B |
| August 20, 2026 | 210.17B |
| August 19, 2026 | 212.74B |
| August 18, 2026 | 207.09B |
| August 17, 2026 | 204.93B |
| August 14, 2026 | 204.47B |
| August 13, 2026 | 204.53B |
| August 12, 2026 | 201.74B |
| August 11, 2026 | 203.50B |
| August 10, 2026 | 205.95B |
| August 07, 2026 | 204.30B |
| August 06, 2026 | 201.11B |
| August 05, 2026 | 198.89B |
| August 04, 2026 | 196.61B |
| August 03, 2026 | 194.44B |
| July 31, 2026 | 194.33B |
| July 30, 2026 | 193.76B |
| July 29, 2026 | 195.13B |
| July 28, 2026 | 195.70B |
| July 27, 2026 | 192.39B |
| July 24, 2026 | 191.65B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Johnson & Johnson | 644.86B |
| Eli Lilly & Co. | 1.122T |
| Merck & Co., Inc. | 403.00B |
| Bristol Myers Squibb Co. | 158.92B |
| Viatris, Inc. | 32.55B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -246.00M |
| Revenue (Quarterly) | 15.03B |
| Total Expenses (Quarterly) | 15.29B |
| EPS Diluted (Quarterly) | -0.0435 |
| Gross Profit Margin (Quarterly) | 62.94% |
| Profit Margin (Quarterly) | -1.64% |
| Earnings Yield | 2.72% |
| Operating Earnings Yield | 10.67% |
| Normalized Earnings Yield | 8.715 |